Cell Rep Med
. 2022 Aug 16;3(8):100718.
doi: 10.1016/j.xcrm.2022.100718.
Hemagglutinin stalk-binding antibodies enhance effectiveness of neuraminidase inhibitors against influenza via Fc-dependent effector functions
Ali Zhang 1 , Hanu Chaudhari 1 , Yonathan Agung 1 , Michael R D'Agostino 1 , Jann C Ang 1 , Yona Tugg 1 , Matthew S Miller 2
Affiliations
- PMID: 35977467
- DOI: 10.1016/j.xcrm.2022.100718
Abstract
The conserved hemagglutinin stalk domain is an attractive target for broadly effective antibody-based therapeutics and next-generation universal influenza vaccines. Protection provided by hemagglutinin stalk-binding antibodies is principally mediated through activation of immune effector cells. Titers of stalk-binding antibodies are highly variable on an individual level and tend to increase with age as a result of increasing exposures to influenza virus. In our study, we show that stalk-binding antibodies cooperate with neuraminidase inhibitors to protect against influenza virus infection in an Fc-dependent manner. These data suggest that the effectiveness of neuraminidase inhibitors is likely influenced by an individual's titers of stalk-binding antibodies and that neuraminidase inhibitors may enhance the effectiveness of future stalk-binding monoclonal antibody-based treatments.
Keywords: Fc receptors; Fc-dependent effector funtions; NA inhibitors; antibodies; antibody-dependent cell cytotoxicity; antibody-dependent cellular cytotoxicity; antivirals; broadly neutralizing antibodies; influenza virus; oseltamivir.